A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma

Eur J Ophthalmol. 2022 Jan;32(1):NP109-NP113. doi: 10.1177/1120672120962044. Epub 2020 Oct 1.


We report a case of ocular drug toxicity consistent with bilateral Vogt-Koyanagi-Harada (VKH) like disease in a patient with cutaneous melanoma treated with Dabrafenib/Trametinib therapy. A 53-year-old man with a history of metastatic cutaneous melanoma, treated with Dabrafenib/Trametinib, developed a severe acute panuveitis with granulomatous anterior uveitis and multiple serous retinal detachments. The ocular inflammatory reaction was classified as a bilateral Vogt-Koyanagi-Harada disease. Intraocular inflammation resolved after discontinuation of chemotherapeutic agents and aggressive topical and systemic corticosteroid therapy. The present case outlines the importance of recognizing VKH-like syndrome as a possible consequence of therapy with dabrafenib and trametinib.

Keywords: Immunology; RETINA; UVEA; UVEITIS; choroidal/retinal inflammation; panuveitis; pharmacology; systemic drug retinal toxicity.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Imidazoles
  • Male
  • Melanoma* / drug therapy
  • Middle Aged
  • Oximes
  • Pyridones
  • Pyrimidinones
  • Skin Neoplasms* / drug therapy
  • Uveitis*
  • Uveomeningoencephalitic Syndrome* / chemically induced
  • Uveomeningoencephalitic Syndrome* / diagnosis
  • Uveomeningoencephalitic Syndrome* / drug therapy


  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib
  • dabrafenib